1.Progress in the diagnosis and treatment of pediatric myocarditis
International Journal of Pediatrics 2023;50(8):539-543
Myocarditis is an inflammatory disease of myocardium caused by a variety of factors.The most common etiology is enterovirus, followed by respiratory viruses, especially the new coronaviruses, mycoplasma, rickettsia, and toxoplasma, etc.The probability of arrhythmia is relatively high in myocarditis due to increased myocardial susceptibility, and its type may be suggestive of disease progression and prognosis.Electrophysiological changes in the cardio-myocytes are observed by electrocardiography and ambulatory electrocardiography.Echocardiography and cardiac magnetic resonance are used to detect specific changes in the internal structure of the myocardium and left ventricular systolic function and to assist in the diagnosis.For the treatment of myocarditis, in addition to general treatment, according to the needs of the condition, intravenous immunoglobulin, glucocorticoids, and receptor antagonists of some cytokines can be used.The prognosis of pediatric myocarditis is related to the type of myocarditis, the speed of progression, the degree of myocardial damage, the electrophysiological changes and the structural changes of the heart.
2.Drug eruption caused by ziprasidone: a case report
Jiakun HONG ; Yanbing SUN ; Xiaobing LIU
Sichuan Mental Health 2022;35(4):370-372
This paper reported a case of drug eruption in a male patient with first-episode schizophrenia. The patient received ziprasidone monotherapy, and experienced post-treatment remission of schizophrenic symptoms, while accompanied by drug eruption with fever and elevated white blood cell count. Even with antiallergic treatment, the eruption did not subside without discontinuation of ziprasidone, whereas the eruption resolved after discontinuation of ziprasidone. This case suggested that individual allergy history should be taken into account during the use of ziprasidone, and timely intervention of adverse skin reactions was essential to prevent the development of severe drug eruption.